Innate Pharma (IPHYF) Short Interest Ratio & Short Volume $2.90 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Innate Pharma Short Interest DataInnate Pharma (IPHYF) has a short interest of 1,600 shares. This marks a -61.90% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 1,445 shares to cover all short positions.Current Short Interest1,600 sharesPrevious Short Interest4,200 sharesChange Vs. Previous Month-61.90%Dollar Volume Sold Short$2,048.00Short Interest Ratio0.0 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares80,210,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume0 sharesAverage Trading Volume1,445 sharesToday's Volume Vs. Average0% Short Selling Innate Pharma? Sign up to receive the latest short interest report for Innate Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIPHYF Short Interest Over TimeIPHYF Days to Cover Over TimeIPHYF Percentage of Float Shorted Over Time Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Innate Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/20241,600 shares $2,048.00 -61.9%N/A0 $1.28 11/15/20244,200 shares $5,376.00 -14.3%N/A42 $1.28 10/31/20244,900 shares $11,000.50 -17.0%N/A0 $2.25 10/15/20245,900 shares $13,245.50 -1.7%N/A0 $2.25 9/30/20246,000 shares $13,470.00 +22.5%N/A10 $2.25 9/15/20244,900 shares $11,270.00 No ChangeN/A0 $2.30 Get the Latest News and Ratings for IPHYF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. 8/31/20244,900 shares $11,270.00 -21.0%N/A24.5 $2.30 8/15/20246,200 shares $13,020.00 -8.8%N/A12.4 $2.10 7/31/20246,800 shares $13,124.68 +23.6%N/A0 $1.93 7/15/20245,500 shares $10,615.55 No ChangeN/A55 $1.93 6/30/20245,500 shares $13,695.00 -30.4%N/A0 $2.49 6/15/20247,900 shares $19,671.00 +43.6%N/A7.2 $2.49 5/31/20245,500 shares $12,100.00 No ChangeN/A55 $2.20 5/15/20245,500 shares $12,100.00 -6.8%N/A2.5 $2.20 4/30/20245,900 shares $15,635.00 -1.7%N/A0 $2.65 4/15/20246,000 shares $15,900.00 +3.5%N/A60 $2.65 3/31/20245,800 shares $14,964.00 No ChangeN/A29 $2.58 3/15/20245,800 shares $14,152.00 +1.8%N/A58 $2.44 2/29/20245,700 shares $16,188.00 No ChangeN/A0 $2.84 2/15/20245,700 shares $16,188.00 -5.0%N/A0 $2.84 1/15/20244,800 shares $13,632.00 +108.7%N/A48 $2.84 12/31/20232,300 shares $6,532.00 -48.9%N/A4.5 $2.84 12/15/20234,500 shares $11,475.00 +650.0%N/A22.5 $2.55 11/30/2023600 shares $1,434.00 +500.0%N/A0 $2.39 11/15/2023100 shares $239.00 No ChangeN/A1 $2.39 10/15/20239,800 shares $22,625.26 +9,700.0%N/A19.6 $2.31 9/30/2023100 shares $300.00 No ChangeN/A0 $3.00 8/31/202311,600 shares $33,698.00 +11,500.0%N/A43.5 $2.91 8/15/2023100 shares $291.00 -75.0%N/A1 $2.91 7/31/2023400 shares $1,196.00 No ChangeN/A4 $2.99 7/15/2023400 shares $1,232.00 +33.3%N/A4 $3.08 6/30/2023300 shares $1,008.00 +200.0%N/A3 $3.36 6/15/2023100 shares $334.00 -80.0%N/A0.3 $3.34 5/31/2023500 shares $1,465.00 +400.0%N/A0 $2.93 5/15/2023100 shares $293.00 -75.0%N/A1 $2.93 4/30/2023400 shares $1,152.00 +100.0%N/A4 $2.88 4/15/2023200 shares $542.00 -97.8%N/A0 $2.71 3/31/20239,200 shares $24,932.00 -27.6%N/A92 $2.71 3/15/202312,700 shares $39,497.00 +1,487.5%N/A63.5 $3.11 2/28/2023800 shares $2,344.00 +14.3%N/A8 $2.93Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW 2/15/2023700 shares $2,408.00 -95.5%N/A0 $3.44 1/31/202315,700 shares $54,008.00 +15,600.0%N/A52.3 $3.44 1/15/2023100 shares $347.00 -97.1%N/A0.3 $3.47 12/30/20223,500 shares $11,445.00 -60.7%N/A0.7 $3.27 12/15/20228,900 shares $20,648.00 +8,800.0%N/A22.3 $2.32 11/30/2022100 shares $218.88 -90.9%N/A1 $2.19 11/15/20221,100 shares $2,519.00 -80.4%N/A1.1 $2.29 10/31/20225,600 shares $11,697.84 +30.2%N/A56 $2.09 10/15/20224,300 shares $8,901.00 +4,200.0%N/A2.3 $2.07 9/30/2022100 shares $193.00 -66.7%N/A1 $1.93 9/15/2022300 shares $780.00 -97.7%N/A1.5 $2.60 8/31/202212,800 shares $35,840.00 +236.8%N/A8.5 $2.80 8/15/20223,800 shares $10,564.00 +11.8%N/A12.7 $2.78 7/31/20223,400 shares $10,744.00 +6.3%N/A34 $3.16 7/15/20223,200 shares $8,640.00 -3.0%N/A32 $2.70 6/30/20223,300 shares $8,580.00 -15.4%N/A1.2 $2.60 6/15/20223,900 shares $10,803.00 -54.7%N/A39 $2.77 5/31/20228,600 shares $24,338.00 +34.4%N/A86 $2.83 5/15/20226,400 shares $18,112.00 -4.5%N/A32 $2.83 4/30/20226,700 shares $18,391.50 +8.1%N/A67 $2.75 4/15/20226,200 shares $18,910.00 +51.2%N/A12.4 $3.05 3/31/20224,100 shares $14,186.00 -93.9%N/A41 $3.46 3/15/202267,000 shares $241,870.00 -10.8%N/A0 $3.61 2/28/202275,100 shares $271,111.00 +1,004.4%N/A751 $3.61 2/15/20226,800 shares $25,228.00 -70.0%N/A5.7 $3.71 1/31/202222,700 shares $85,579.00 +57.6%N/A37.8 $3.77 1/15/202214,400 shares $62,640.00 +5.1%N/A0 $4.35 12/31/202113,700 shares $59,595.00 +407.4%N/A5.1 $4.35 12/15/20212,700 shares $13,743.00 -52.6%N/A1.4 $5.09 11/30/20215,700 shares $28,618.56 +1.8%N/A6.3 $5.02 11/15/20215,600 shares $28,000.00 -51.7%N/A3.1 $5.00 10/29/202111,600 shares $65,656.00 -6.5%N/A4.1 $5.66 10/15/202112,400 shares $73,160.00 +63.2%N/A6.5 $5.90 9/30/20217,600 shares $47,500.00 -26.2%N/A0.7 $6.25 9/15/202110,300 shares $58,504.00 -94.6%N/A0.7 $5.68 8/31/2021191,300 shares $679,115.00 -49.5%N/A956.5 $3.55 8/13/2021378,500 shares $1.22 million -0.1%N/A3785 $3.22 7/30/2021378,700 shares $1.19 million +0.2%N/A3787 $3.15 7/15/2021378,100 shares $1.23 million +0.0%N/A315.1 $3.25 6/30/2021378,000 shares $1.23 million No ChangeN/A315 $3.25 6/15/2021378,000 shares $1.34 million -0.5%N/A3780 $3.55 5/28/2021379,800 shares $1.44 million -10.3%N/A0 $3.80 5/14/2021423,400 shares $1.74 million +2.3%N/A4234 $4.11 4/30/2021414,000 shares $1.85 million +3.3%N/A828 $4.48 4/15/2021400,700 shares $1.80 million +1,627.2%N/A4007 $4.48 3/31/202123,200 shares $102,506.88 -94.2%N/A77.3 $4.42 3/15/2021401,900 shares $1.82 million 0.0%N/A4019 $4.53 2/26/2021402,000 shares $1.79 million -0.1%N/A1340 $4.46 2/12/2021402,300 shares $1.94 million -0.7%N/A365.7 $4.81 1/29/2021405,200 shares $1.75 million No ChangeN/A4052 $4.33Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW 1/15/2021405,500 shares $1.91 million 0.0%N/A1013.8 $4.72 12/31/2020405,200 shares $1.72 million -0.1%N/A368.4 $4.24 12/15/2020405,500 shares $1.77 million 0.0%N/A1013.8 $4.36 11/30/2020405,600 shares $2.21 million -0.4%N/A450.7 $5.45 11/15/2020407,100 shares $1.81 million No ChangeN/A1017.8 $4.45 10/30/2020407,100 shares $1.51 million +0.2%N/A508.9 $3.70 10/15/2020406,300 shares $1.66 million -0.1%N/A677.2 $4.08 9/30/2020406,600 shares $1.55 million -3.1%N/A4066 $3.80 9/15/2020419,700 shares $1.73 million +3.3%N/A182.5 $4.13 8/31/2020406,200 shares $2.62 million No ChangeN/A2031 $6.45 8/14/2020406,200 shares $2.62 million +0.2%N/A1354 $6.44 7/31/2020405,500 shares $2.56 million No ChangeN/A0 $6.33 7/15/2020405,500 shares $2.56 million No ChangeN/A4055 $6.33 6/30/2020405,500 shares $2.46 million +1,897.5%N/A2027.5 $6.06 6/15/202020,300 shares $128,905.00 +0.5%N/A40.6 $6.35 5/29/202020,200 shares $125,846.00 -95.0%N/A0 $6.23 5/15/2020405,200 shares $2.86 million No ChangeN/A193 $7.07 4/30/2020405,200 shares $2.66 million No ChangeN/A4052 $6.57 4/15/2020405,200 shares $2.24 million 0.0%N/A405.2 $5.53 3/31/2020405,300 shares $2.72 million -0.6%N/A579 $6.70 3/13/2020407,900 shares $2.00 million +0.6%N/A4079 $4.90 2/28/2020405,300 shares $2.97 million -4.8%N/A4053 $7.34 2/14/2020425,900 shares $3.05 million -1.2%N/A2129.5 $7.17 1/31/2020430,900 shares $3.23 million -9.0%N/A718.2 $7.50 1/15/2020473,700 shares $3.57 million +12.0%N/A197.4 $7.53 12/31/2019422,800 shares $3.17 million -5.5%N/A325.2 $7.50 IPHYF Short Interest - Frequently Asked Questions What is Innate Pharma's current short interest? Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been covered or closed out. As of November 30th, investors have sold 1,600 shares of IPHYF short. Learn More on Innate Pharma's current short interest. Is Innate Pharma's short interest increasing or decreasing? Innate Pharma saw a decrease in short interest during the month of November. As of November 30th, there was short interest totaling 1,600 shares, a decrease of 61.9% from the previous total of 4,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Innate Pharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Innate Pharma: enGene Holdings Inc. (4.14%), Voyager Therapeutics, Inc. (4.69%), Valneva SE (0.04%), Jasper Therapeutics, Inc. (18.29%), 4D Molecular Therapeutics, Inc. (18.43%), Fate Therapeutics, Inc. (9.97%), iTeos Therapeutics, Inc. (6.36%), Tenaya Therapeutics, Inc. (21.42%), Atyr PHARMA INC (2.65%), C4 Therapeutics, Inc. (11.32%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Innate Pharma stock? Short selling IPHYF is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Innate Pharma? A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHYF, which in turn drives the price of the stock up even further. How often is Innate Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHYF, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies enGene Short Interest Voyager Therapeutics Short Interest Valneva Short Interest Jasper Therapeutics Short Interest 4D Molecular Therapeutics Short Interest Fate Therapeutics Short Interest iTeos Therapeutics Short Interest Tenaya Therapeutics Short Interest Atyr PHARMA Short Interest C4 Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:IPHYF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPHYF Stock Alerts